Skip to content

Outcome of Steroid Therapy for Myocardial Inflammation in Scleroderma

Outcome of Myocardial Inflammation After Steroid Therapy in Thai Systemic Sclerosis Patients: an Open Label Study

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03607071
Enrollment
20
Registered
2018-07-31
Start date
2018-05-15
Completion date
2019-06-30
Last updated
2020-09-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myocardial Inflammation

Brief summary

Primary myocardial involvement is common in scleroderma, effected to pericardium, vascular, conducting defect and especially myocardium. Cardiac MRI is widely used for assessment of cardiac involvement in scleroderma, both structural and functional pathology. Cardiac MRI has a diagnostic accuracy of 85% for the detection of myocardial inflammation. Nowadays, the treatment of myocardial inflammation in scleroderma is uncertain. The investigator's study aims to define the cardiac outcome after moderate dose steroid therapy in the patients who have myocardial inflammation detection by cardiac MRI.

Interventions

DRUGPrednisolone and taper

Prednisolone 30 mg/d and taper 5-10 mg per 2 weeks until off at week 24.

Sponsors

Khon Kaen University
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

Moderate dose steroid therapy

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

• The adult scleroderma patients who were defined as having myocardial inflammation by cardiac MRI.

Exclusion criteria

* Current infection that needs systemic antibiotic therapy * Active viral hepatitis B or C * Uncontrolled diabetes mellitus

Design outcomes

Primary

MeasureTime frameDescription
Changing of degree of myocarditis evaluated by cardiac MRI after treatment compare to baseline24 weeksMyocarditis is defined as inflammatory disease of the myocardium according to the cardiac MRI Lake Louise criteria at least 2 of the following criteria: 1. Regional or global myocardial signal intensity increased in the T2-weighted images; 2. Increased global myocardial early enhancement ratio between the myocardium and skeletal muscle in the gadolinium-enhanced T1-weighted images; and, 3. At least 1 focal lesion with nonischemic regional distribution in the inversion-recovery-prepared, gadolinium-enhanced, T1-weighted images (delayed enhancement). Response to treatment is defined as any reducing of degree of myocarditis without any progression of myocardial fibrosis or scarring when compared to the cardiac MRI baseline

Countries

Thailand

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 16, 2026